1. Home
  2. PHAR vs LYTS Comparison

PHAR vs LYTS Comparison

Compare PHAR & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$16.31

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo LSI Industries Inc.

LYTS

LSI Industries Inc.

HOLD

Current Price

$18.49

Market Cap

601.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
LYTS
Founded
1988
1976
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building Products
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
601.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PHAR
LYTS
Price
$16.31
$18.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$38.00
$27.50
AVG Volume (30 Days)
22.5K
147.9K
Earning Date
11-06-2025
01-22-2026
Dividend Yield
N/A
1.08%
EPS Growth
N/A
2.57
EPS
0.00
0.80
Revenue
$362,274,000.00
$592,531,000.00
Revenue This Year
$24.80
$6.26
Revenue Next Year
$6.84
$7.45
P/E Ratio
$2,946.57
$23.09
Revenue Growth
26.78
22.35
52 Week Low
$7.50
$13.77
52 Week High
$18.12
$25.50

Technical Indicators

Market Signals
Indicator
PHAR
LYTS
Relative Strength Index (RSI) 51.06 41.44
Support Level $16.23 $18.33
Resistance Level $17.00 $19.43
Average True Range (ATR) 0.75 0.45
MACD -0.16 0.12
Stochastic Oscillator 36.44 37.07

Price Performance

Historical Comparison
PHAR
LYTS

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About LYTS LSI Industries Inc.

LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.

Share on Social Networks: